Enzon Pharmaceuticals Inc (NASDAQ:ENZN) major shareholder Carl C. Icahn acquired 694,023 shares of the firm’s stock in a transaction dated Monday, November 28th. The stock was bought at an average cost of $0.41 per share, with a total value of $284,549.43. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Enzon Pharmaceuticals Inc (NASDAQ:ENZN) opened at 0.4799 on Thursday. The firm has a market cap of $21.22 million and a PE ratio of 1.3331. Enzon Pharmaceuticals Inc has a one year low of $0.35 and a one year high of $1.10. The stock has a 50 day moving average price of $0.38 and a 200 day moving average price of $0.39.

TRADEMARK VIOLATION WARNING: This story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another domain, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this story can be read at https://www.thecerbatgem.com/2016/12/01/carl-c-icahn-buys-694023-shares-of-enzon-pharmaceuticals-inc-enzn-stock.html.

About Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products: PegIntron, Sylatron, Macugen and CIMZIA. The Company has no clinical operations and limited corporate operations. PegIntron is used both as a monotherapy and in combination with REBETOL (ribavirin) capsules for the treatment of chronic hepatitis C.

5 Day Chart for NASDAQ:ENZN

Receive News & Stock Ratings for Enzon Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzon Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.